Clonidine transdermal and Saxagliptin Hydrochloride

• Generic Name: clonidine
• Dosage Forms: n.a.
• Other Brand Names: Catapres, Kapvay, Catapres-TTS, Duraclon, Catapres-TTS-1, Catapres-TTS-2, Catapres-TTS-3

Clonidine lowers blood pressure by decreasing the levels of certain chemicals in your blood. This allows your blood vessels to relax and your heart to beat more slowly and easily.

Clonidine transdermal (skin patch) is used to treat hypertension (high blood pressure). It is sometimes used together with other blood pressure medications.

Clonidine transdermal may also be used for purposes not listed in this medication guide.

• Generic Name: saxagliptin
• Dosage Forms: n.a.
• Other Brand Names: Onglyza

Used as monotherapy as an adjunct to diet and exercise for management of type 2 diabetes mellitus in patients whose hyperglycemia cannot be controlled by diet and exercise alone.

Used in combination with metformin (separately or as fixed combination of saxagliptin and extended-release metformin), a sulfonylurea, a thiazolidinedione (e.g., a peroxisome proliferator-activated receptor-γ [PPAR-γ] agonist) or insulin for management of type 2 diabetes mellitus in patients who do not achieve adequate glycemic control with diet, exercise, and metformin, sulfonylurea, thiazolidinedione monotherapy, and/or insulin. Patients initially receiving an oral antidiabetic agent will eventually require multiple oral antidiabetic agents of different therapeutic classes and/or insulin for adequate glycemic control because of declining β2-cell function with disease progression.

The fixed combination of saxagliptin and dapagliflozin is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) suggests a DPP-4 inhibitor as one of several alternatives for initial monotherapy in patients with metformin contraindications (e.g., renal disease, hepatic disease, GI intolerance, risk of lactic acidosis). DPP-4 inhibitors also recommended as part of combination therapy, particularly with both postprandial and fasting plasma glucose elevations.

Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is required in these conditions.